This is a multicenter, open-label, multiple-dose dose finding and expansion study to evaluate
the safety, tolerability, pharmacokinetic(PK) profile, and anti-tumor efficacy of SKB410 for
injection in patients with advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.